BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients being treated for leukemia and multiple myeloma for a bone marrow transplant. TBI involves irradiation of the entire body, elevating the need for precision, accuracy and homogeneity in radiation dose delivery

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment and dosing of all 5 planned cohorts of healthy adult volunteers in the single-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection

Technology Enables Clinicians to Non-Invasively Evaluate Brain Blood Flow Characteristics for Management of Patients with Neurological Disease

Hospital for Special Surgery (HSS) will present Paul Pellicci, MD, Chief Emeritus of the Hip Service, with the Lifetime Achievement Award at the Hospital’s 35th Tribute Dinner.

National Philanthropy Day in Colorado is accepting nominations for outstanding philanthropic individuals, businesses, organizations and foundations.

Pivot Health announced it is releasing its short term medical (STM) insurance products in seven additional states.

Gilead Sciences, Inc. announced today that the China Drug Administration (CDA) has approved Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

The preliminary notice of meeting including the agenda and the draft resolutions has been published in the Bulletin des Annonces Légales Obligatoires (BALO) on 20 April 2018 and the notice of meeting in the BALO on 9 May 2018.

Vedanta Biosciences announced that Chief Executive Officer, Bernat Olle, Ph.D., will present at the Jefferies 2018 Global Healthcare Conference.

TherapeuticsMD, Inc. today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia due to menopause.